
    
      Patients will be treated for a maximum of 6 cycles (21 days each), in the absence of
      unacceptable toxicity or disease progression or consent withdrawal. All patients will be
      followed for disease progression documentation and for patient status until up to one year
      after the primary analysis cutoff date.
    
  